The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn ... reflecting strong performance of new products and the investment we've put ...
This eases the user's understanding of the market thoroughly, while also gaining knowledge about Anxiety Disorder Treatment market opportunities and the dominant players Pfizer Inc, Merck KGaA, Sanofi ...
Nigeria, the giant of Africa, has recently experienced a great downturn in its economy, leading to the exodus of several ...
GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...
€400 million upfront payment from restructured GSK collaboration reflected in financials ... as well as co-heading European healthcare investments at 3i Group plc, a UK-listed private equity firm with ...
The Motley Fool UK has recommended AstraZeneca Plc and GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official ...
While uncertainty often casts a shadow on the Street, U.S. investors welcomed the presidential and congressional election results with a late-night surge that carried into this morning. The Dow Jones ...
Considering and investment of £20k in these five FTSE 100 dividend stocks could potentially generate just over £1,600 in annual passive income.
The Cambridge-GSK Translational Immunology Collaboration (CG-TIC) brings together GSK’s expertise in the science of the immune system, AI and clinical development with Cambridge’s complementary ...
They launched some new products namely ... This follows a global transaction between GlaxoSmithKline plc, UK (GSK) and Novartis AG, Switzerland (Novartis) which was completed in March 2015 ...
Two of GSK Plc’s blockbuster vaccines delivered lower than expected sales in the third quarter after the British drugmaker was hit by issues with access to the shots in the US.
Moderna MRNA is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate ...